JaxBio Is Proud to Be a Part of Revolutionizing Cancer Diagnosis and Management with Our Simple, Sensitive Blood Test -

This approach directly addresses one of the biggest drawbacks in current ctDNA testing methods, potentially improving the accuracy and reliability of liquid biopsies for cancer diagnosis and monitoring. To learn more visit

4. Characterizing resistance mechanisms: Serial ctDNA monitoring can reveal new therapy options or the need to switch treatments. Dr. Jingquan Jia presented the limitations of ctDNA testing:

2. Predicting recurrence: Positive ctDNA before adjuvant chemotherapy indicated poor recurrence-free survival in resected CCA patients. 3. Identifying actionable alterations: ctDNA testing identified treatment-relevant alterations in 40-55% of BTC patients.

1. Confirming diagnosis: A study using a 4-gene panel showed 93% specificity and 83% sensitivity for diagnosing cholangiocarcinoma (CCA) a type of BTC.

BTC is a tricky cancer that is hard to diagnose with high recurrance rates. Dr. Laura Goff argued in favor of ctDNA monitoring, citing several advantages:

Together, we can create a world where cancer care is as individual as you are. @uicc #WorldCancerDay #UnitedByUnique #Jaxbio

Here's to our journey so far and the promising future that lies ahead!